APA (7th ed.) Citation

M, C., RD, R., K, B., S, D., AM, A., L, J., . . . RR, F. (2026). Heparanase inhibition prevents glycocalyx damage and albuminuria in experimental minimal change disease. Clinical and translational medicine, 16(6), e70706. https://doi.org/10.1002/ctm2.70706

Chicago Style (17th ed.) Citation

M, Crompton, et al. "Heparanase Inhibition Prevents Glycocalyx Damage and Albuminuria in Experimental Minimal Change Disease." Clinical and Translational Medicine 16, no. 6 (2026): e70706. https://doi.org/10.1002/ctm2.70706.

MLA (9th ed.) Citation

M, Crompton, et al. "Heparanase Inhibition Prevents Glycocalyx Damage and Albuminuria in Experimental Minimal Change Disease." Clinical and Translational Medicine, vol. 16, no. 6, 2026, p. e70706, https://doi.org/10.1002/ctm2.70706.